Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis

Blood (2024) 143 (14): 1399–1413.

https://doi.org/10.1182/blood.2023021349

Published: 2024

Includes: Supplemental data

Journal Articles

First-Hit SETBP1 Mutations Cause a Myeloproliferative Disorder with Bone Marrow Fibrosis

Blood (2023) 142 (Supplement 1): 4135.

https://doi.org/10.1182/blood-2023-189094

Published: 2023

Journal Articles

Effects of CD24 "Don't Eat Me" Signal Blockade in Combination with Anti-CD47 and Rituximab in Mantle-Cell Lymphoma

Andrea Aroldi, Mario Mauri, Matteo Villa, Federica Malighetti, Federica Cocito, Claudia Voena, Roberto Chiarle, Luca Mologni, Rocco Piazza, Carlo Gambacorti-Passerini

Blood (2022) 140 (Supplement 1): 3136–3138.

https://doi.org/10.1182/blood-2022-159247

Published: 2022

Journal Articles

Next-generation ALK inhibitors are highly active in ALK-positive large B-cell lymphoma

Blood (2022) 140 (16): 1822–1826.

https://doi.org/10.1182/blood.2022015443

Published: 2022

Includes: Multimedia, Supplemental data

Journal Articles

Congenital anemia reveals distinct targeting mechanisms for master transcription factor GATA1

Blood (2022) 139 (16): 2534–2546.

https://doi.org/10.1182/blood.2021013753

Published: 2022

Includes: Supplemental data

Journal Articles

Tyrosine phosphatases regulate resistance to ALK inhibitors in ALK + anaplastic large cell lymphoma

Blood (2022) 139 (5): 717–731.

https://doi.org/10.1182/blood.2020008136

Published: 2022

Includes: Supplemental data

Journal Articles

CD24/Siglec-10 "Don't Eat Me" Signal Blockade Is a Potential Immunotherapeutic Target in Mantle-Cell Lymphoma

Andrea Aroldi, Mario Mauri, Matteo Parma, Elisabetta Terruzzi, Marilena Fedele, Paola Perfetti, Federica Cocito, Luca Mologni, Roberto Chiarle, Rocco Piazza, Carlo Gambacorti-Passerini

Blood (2021) 138 (Supplement 1): 2276.

https://doi.org/10.1182/blood-2021-154086

Published: 2021

Journal Articles

IL10RA modulates crizotinib sensitivity in NPM1-ALK + anaplastic large cell lymphoma

Blood (2020) 136 (14): 1657–1669.

https://doi.org/10.1182/blood.2019003793

Published: 2020

Includes: Supplemental data

Journal Articles

Identifying Novel Mechanisms of Resistance to Tyrosine Kinase Inhibitors in Anaplastic Large Cell Lymphoma

Elif Atabay, PhD, Qi Wang, PhD, Ambrogio Chiara, PhD, Taek-Chin Cheong, PhD, Silvia Peola, Geeta G Sharma, PhD, Luca Mologni, PhD, Carlo Gambacorti-Passerini, MD, Claudia Voena, PhD, Roberto Chiarle, MD

Blood (2019) 134 (Supplement_1): 5060.

https://doi.org/10.1182/blood-2019-132188

Published: 2019

Journal Articles

FBXO11 Is Recurrently Mutated in Burkitt Lymphoma and Its Inactivation Accelerates Lymphomagenesis in Eμ-Myc mice

Chiara Pighi, Mara Compagno, Taek-Chin Cheong, Teresa Poggio, Qi Wang, Fernanda Langellotto, Anoop Sendamarai, Kyriacos Markianos, Paola Francia Di Celle, Alberto Zamò, Roberto Chiarle, MD

Blood (2017) 130 (Supplement 1): 1219.

https://doi.org/10.1182/blood.V130.Suppl_1.1219.1219

Published: 2017

Journal Articles

Myc and Bcl2 Overexpression and Traslocation Assessed By Immunohystochemistry (IHC) and FISH: Retrospective Analysis in a Series of De Novo DLBCL Homogeneously Treated with Rituximab-CHOP

Chiara Ciochetto, Maria Stella Scalzo, Barbara Botto, Alessia Castellino, Annalisa Chiappella, MD, Mattia Novo, Maura Nicolosi, Elisa Santambrogio, Federica Cavallo, MD, Paola Ghione, Andrea Evangelista, MSc, Giovannino Ciccone, MD PhD, Roberto Chiarle, MD, Domenico Novero, MD, Umberto Vitolo, MD

Blood (2016) 128 (22): 5305.

https://doi.org/10.1182/blood.V128.22.5305.5305

Published: 2016

Journal Articles

Redundant and nonredundant roles for Cdc42 and Rac1 in lymphomas developed in NPM-ALK transgenic mice

Ramesh Choudhari, Valerio Giacomo Minero, Matteo Menotti, Roberta Pulito, Cord Brakebusch, Mara Compagno, Claudia Voena, Chiara Ambrogio, Roberto Chiarle

Blood (2016) 127 (10): 1297–1306.

https://doi.org/10.1182/blood-2015-11-683052

Published: 2016

Includes: Supplemental data

Journal Articles

PI3Kdelta Inhibitors Increase Genomic Instability By Upregulating Aid Expression

Mara Compagno, Wang Qi, Chiara Pighi, Feilong Meng, Taek-Chin Cheong, Teresa Poggio, Fernanda Langellotto, Claudia Voena, Monica Gostissa, Frederick Alt, Roberto Chiarle

Blood (2015) 126 (23): 164.

https://doi.org/10.1182/blood.V126.23.164.164

Published: 2015

Journal Articles

De-Novo Diffuse Large B Cell Lymphoma (DLBCL) Treated with Rituximab (R)-CHOP: Definition and Validation of a Prognostic Score Model Based on MYC, BCL2 and BCL6 Expression By Immunohistochemistry (IHC)

Barbara Botto, Alessia Castellino, Annalisa Chiappella, Mattia Novo, Luigi Zattera, Federica Cavallo, Paola Ghione, Andrea Evangelista, Chiara Ciochetto, Giovannino Ciccone, Maria Stella Scalzo, Roberto Chiarle, Domenico Novero, Umberto Vitolo

Blood (2015) 126 (23): 2650.

https://doi.org/10.1182/blood.V126.23.2650.2650

Published: 2015

Journal Articles

FBXO11, a Regulator of BCL6 Stability, Is Recurrently Mutated in Burkitt Lymphoma

Chiara Pighi, Mara Compagno, Qi Wang, Taek-Chin Cheong, Teresa Poggio, Fernanda Langellotto, Paola Francia di Celle, Alberto Zamò, Roberto Chiarle

Blood (2015) 126 (23): 3673.

https://doi.org/10.1182/blood.V126.23.3673.3673

Published: 2015

Journal Articles

The BRAF Pseudogene Is a Proto-Oncogenic Competitive Endogenous RNA

Florian Karreth, PhD, Markus Reschke, PhD, Bjoern Chapuy, MD PhD, Margaret A. Shipp, MD, Roberto Chiarle, MD, Pier Paolo Pandolfi, MD PhD

Blood (2014) 124 (21): 263.

https://doi.org/10.1182/blood.V124.21.263.263

Published: 2014

Journal Articles

The lymphoma-associated NPM-ALK oncogene elicits a p16INK4a/pRb-dependent tumor-suppressive pathway

Paola Martinelli, Paola Bonetti, Cristina Sironi, Giancarlo Pruneri, Caterina Fumagalli, Paola Rafaniello Raviele, Sara Volorio, Stefano Pileri, Roberto Chiarle, Fiona Kate Elizabeth McDuff, Betsabeh Khoramian Tusi, Suzanne D. Turner, Giorgio Inghirami, Pier Giuseppe Pelicci, Emanuela Colombo

Blood (2011) 117 (24): 6617–6626.

https://doi.org/10.1182/blood-2010-08-301135

Published: 2011

Includes: Supplemental data

Journal Articles

The enzymatic activity of 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase is enhanced by NPM-ALK: new insights in ALK-mediated pathogenesis and the treatment of ALCL

Francesco E. Boccalatte, Claudia Voena, Chiara Riganti, Amalia Bosia, Lucia D'Amico, Ludovica Riera, Mangeng Cheng, Bruce Ruggeri, Ole N. Jensen, Valerie L. Goss, Kimberly Lee, Julie Nardone, John Rush, Roberto D. Polakiewicz, Michael J. Comb, Roberto Chiarle, Giorgio Inghirami

Blood (2009) 113 (12): 2776–2790.

https://doi.org/10.1182/blood-2008-06-161018

Published: 2009

Includes: Supplemental data

Journal Articles

In the absence of IGF-1 signaling, IFN-γ suppresses human malignant T-cell growth

Laura Conti, Gabriella Regis, Angela Longo, Paola Bernabei, Roberto Chiarle, Mirella Giovarelli, Francesco Novelli

Blood (2006) 109 (6): 2496–2504.

https://doi.org/10.1182/blood-2006-07-034231

Published: 2006

Journal Articles

Ablation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas

Roberto Piva, Roberto Chiarle, Andrea D. Manazza, Riccardo Taulli, William Simmons, Chiara Ambrogio, Valentina D'Escamard, Elisa Pellegrino, Carola Ponzetto, Giorgio Palestro, Giorgio Inghirami

Blood (2006) 107 (2): 689–697.

https://doi.org/10.1182/blood-2005-05-2125

Published: 2006

NARROW

First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis

First-Hit SETBP1 Mutations Cause a Myeloproliferative Disorder with Bone Marrow Fibrosis

Effects of CD24 "Don't Eat Me" Signal Blockade in Combination with Anti-CD47 and Rituximab in Mantle-Cell Lymphoma

Next-generation ALK inhibitors are highly active in ALK-positive large B-cell lymphoma

Congenital anemia reveals distinct targeting mechanisms for master transcription factor GATA1

Tyrosine phosphatases regulate resistance to ALK inhibitors in ALK + anaplastic large cell lymphoma

CD24/Siglec-10 "Don't Eat Me" Signal Blockade Is a Potential Immunotherapeutic Target in Mantle-Cell Lymphoma

IL10RA modulates crizotinib sensitivity in NPM1-ALK + anaplastic large cell lymphoma

Identifying Novel Mechanisms of Resistance to Tyrosine Kinase Inhibitors in Anaplastic Large Cell Lymphoma

FBXO11 Is Recurrently Mutated in Burkitt Lymphoma and Its Inactivation Accelerates Lymphomagenesis in Eμ-Myc mice

Myc and Bcl2 Overexpression and Traslocation Assessed By Immunohystochemistry (IHC) and FISH: Retrospective Analysis in a Series of De Novo DLBCL Homogeneously Treated with Rituximab-CHOP

Redundant and nonredundant roles for Cdc42 and Rac1 in lymphomas developed in NPM-ALK transgenic mice

PI3Kdelta Inhibitors Increase Genomic Instability By Upregulating Aid Expression

De-Novo Diffuse Large B Cell Lymphoma (DLBCL) Treated with Rituximab (R)-CHOP: Definition and Validation of a Prognostic Score Model Based on MYC, BCL2 and BCL6 Expression By Immunohistochemistry (IHC)

FBXO11, a Regulator of BCL6 Stability, Is Recurrently Mutated in Burkitt Lymphoma

The BRAF Pseudogene Is a Proto-Oncogenic Competitive Endogenous RNA

The lymphoma-associated NPM-ALK oncogene elicits a p16INK4a/pRb-dependent tumor-suppressive pathway

The enzymatic activity of 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase is enhanced by NPM-ALK: new insights in ALK-mediated pathogenesis and the treatment of ALCL

In the absence of IGF-1 signaling, IFN-γ suppresses human malignant T-cell growth

Ablation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only